MR Fingerprinting-A Radiogenomic Marker for Diffuse Gliomas.
MR fingerprinting
T1 and T2 relaxation times
brain/central nervous system cancers
gliomas
quantitative maps
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Jan 2022
30 Jan 2022
Historique:
received:
13
12
2021
revised:
22
01
2022
accepted:
28
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
(1) Background: Advanced MR imaging (MRI) of brain tumors is mainly based on qualitative contrast images. MR Fingerprinting (MRF) offers a novel approach. The purpose of this study was to use MRF-derived T1 and T2 relaxation maps to differentiate diffuse gliomas according to isocitrate dehydrogenase (IDH) mutation. (2) Methods: Twenty-four patients with histologically verified diffuse gliomas (14 IDH-mutant, four 1p/19q-codeleted, 10 IDH-wildtype) were enrolled. MRF T1 and T2 relaxation times were compared to apparent diffusion coefficient (ADC), relative cerebral blood volume (rCBV) within solid tumor, peritumoral edema, and normal-appearing white matter (NAWM), using contrast-enhanced MRI, diffusion-, perfusion-, and susceptibility-weighted imaging. For perfusion imaging, a T2* weighted perfusion sequence with leakage correction was used. Correlations of MRF T1 and T2 times with two established conventional sequences for T1 and T2 mapping were assessed (a fast double inversion recovery-based MR sequence ('MP2RAGE') for T1 quantification and a multi-contrast spin echo-based sequence for T2 quantification). (3) Results: MRF T1 and T2 relaxation times were significantly higher in the IDH-mutant than in IDH-wildtype gliomas within the solid part of the tumor (
Identifiants
pubmed: 35158990
pii: cancers14030723
doi: 10.3390/cancers14030723
pmc: PMC8833555
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Austrian Science Fund FWF
ID : KLI 679
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : KLI 917
Pays : Austria
Organisme : FWF Austrian Science Fund
ID : KPKLI679FW
Références
Radiology. 2017 Aug;284(2):316-331
pubmed: 28723281
Magn Reson Med. 2018 Jan;79(1):83-96
pubmed: 28261851
Radiology. 2008 Nov;249(2):601-13
pubmed: 18780827
Radiology. 2019 Aug;292(2):429-437
pubmed: 31210615
Tomography. 2015 Dec;1(2):136-144
pubmed: 26824078
Eur Radiol. 2018 Aug;28(8):3306-3317
pubmed: 29536240
Magn Reson Med. 2015 Dec;74(6):1621-31
pubmed: 25491018
Technol Health Care. 1994 Dec;2(4):247-54
pubmed: 7842309
Magn Reson Med. 2016 Jun;75(6):2303-14
pubmed: 26178439
Magn Reson Med. 2017 Oct;78(4):1452-1457
pubmed: 27790751
Neuroradiology. 2015 Jan;57(1):11-20
pubmed: 25287076
Magn Reson Med. 2017 Sep;78(3):1100-1109
pubmed: 28714279
Clin Cancer Res. 2016 Apr 1;22(7):1632-41
pubmed: 26534967
AJNR Am J Neuroradiol. 2013 Mar;34(3):533-40
pubmed: 22997168
AJNR Am J Neuroradiol. 2018 Aug;39(8):1439-1445
pubmed: 30002055
Invest Radiol. 2004 May;39(5):288-99
pubmed: 15087723
Magn Reson Med. 1988 May;7(1):23-34
pubmed: 3386519
Neuroimage. 2010 Jan 15;49(2):1271-81
pubmed: 19819338
Radiology. 2019 Mar;290(3):659-668
pubmed: 30599101
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1435-1445
pubmed: 31811342
Nature. 2013 Mar 14;495(7440):187-92
pubmed: 23486058
Eur J Radiol. 2021 Jan;134:109466
pubmed: 33307459
Lancet Oncol. 2012 Jul;13(7):707-15
pubmed: 22578793
Sci Rep. 2015 Nov 05;5:16238
pubmed: 26538165
Acta Neurochir Suppl. 2013;118:195-9
pubmed: 23564131
Invest Radiol. 2021 Jan;56(1):1-9
pubmed: 33186141
Curr Neurol Neurosci Rep. 2013 May;13(5):345
pubmed: 23532369
Clin Neurol Neurosurg. 2013 Aug;115(8):1366-70
pubmed: 23351840
Radiographics. 2005 Nov-Dec;25(6):1669-88
pubmed: 16284142
Eur Radiol. 2018 Oct;28(10):4350-4361
pubmed: 29721688
AJNR Am J Neuroradiol. 2019 Jul;40(7):1149-1155
pubmed: 31248860
Nat Med. 2012 Jan 26;18(4):624-9
pubmed: 22281806
Insights Imaging. 2013 Apr;4(2):147-52
pubmed: 23397519
J Magn Reson Imaging. 1992 Sep-Oct;2(5):541-53
pubmed: 1392247
Magn Reson Med. 2016 Jun;75(6):2481-92
pubmed: 26132462
Acad Radiol. 2021 Mar 5;:
pubmed: 33685792
J Clin Oncol. 2009 Sep 1;27(25):4150-4
pubmed: 19636000
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Nat Commun. 2018 Apr 16;9(1):1474
pubmed: 29662077
Magn Reson Imaging. 2018 Dec;54:241-248
pubmed: 30193953
AJNR Am J Neuroradiol. 2017 Mar;38(3):492-499
pubmed: 28034994
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):683-693
pubmed: 32979059
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
MAGMA. 2020 Dec;33(6):783-791
pubmed: 32248322
AJNR Am J Neuroradiol. 2016 Jan;37(1):58-65
pubmed: 26405082
J Magn Reson Imaging. 2005 Jun;21(6):701-8
pubmed: 15906339
Neuro Oncol. 2013 Oct;15(10):1395-404
pubmed: 23925453
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237